Insider Cluster (2 insiders) ·Filed May 1, 2026

RARE

Ultragenyx Pharmaceutical Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago
Insider cluster: 2 insiders, $125K total
Actionable Insight • Neutral

Insider sales are too small to warrant concern. Monitor for any larger insider transactions in the coming weeks, particularly if accompanied by material news. The earnings release itself is the more relevant event for traders.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
RARE ▲ +4.88% at T+60d
NEUTRAL call ✓ call won +4.88% · α vs SPY +1.82% · entry $24.77 → $25.98
Entry anchored
Apr 30, 03:59 PM ET
via exchange tick
T+1d
+0.16%
call +0.16% · α +0.50%
$24.81
settled 5mo ago
T+5d
+5.49%
call +5.49% · α +3.14%
$26.13
settled 5mo ago
T+20d
-7.75%
call -7.75% · α -13.04%
$22.85
settled 4mo ago
T+60d
+4.88%
call +4.88% · α +1.82%
$25.98
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Two Ultragenyx insiders (CFO and Chief Medical Officer) sold a combined $125K in open-market transactions over the past week, representing just 0.005% of market cap. The sales followed the company's earnings release and are negligible relative to company size, indicating routine portfolio management rather than a negative signal.

Key Financial Metrics

Direction
selling
Total Value
$125.2K
Insiders
2

Key Facts

  • CFO Howard Horn sold 4,683 shares at ~$24.90 for $117K on May 1.
  • Chief Medical Officer Eric Crombez sold 344 shares at $24.96 for $9K on May 5.
  • Total insider sales of $125K represent 0.005% of RARE's $2.5B market cap.
  • Sales occurred within one day of the company's May 5 earnings release (8-K Item 2.02).

Financial Impact

Trivial insider selling of $125K total, immaterial to company valuation.

Risk Factors

  • No material risk from these sales; however, continued insider selling at larger volumes could signal management sentiment.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (26 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RARE-1778093500730
12 reports for RARE
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+60▲ +48.73%Apr 2, 2026
Filters
Rows
Reports for RARE — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BEARISH ★ 8/10
$14.85 $15.22▼ −2.49%▼ −3.68%$15.22 (−2.49%)
Sep 1, 2026
4w ago
Press Release
BULLISH ★ 7/10
$26.53 $15.03▼ −43.35%▼ −43.02%$15.22 (−42.63%)
Aug 11, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$26.80 $14.31▼ −46.60%▼ −45.55%$15.22 (−43.21%)
Aug 4, 2026
8w ago
8-K
BULLISH ★ 6/10
$24.93 $26.53▲ +6.42%▲ +7.02%$15.22 (−38.95%)
Aug 4, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$25.81 $25.81· 0.00%▲ +1.24%$15.22 (−41.03%)
Jun 15, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.85 $32.03▲ +28.89%▲ +28.69%$15.22 (−38.75%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 4/10
$23.98 $34.61▲ +44.33%▲ +42.44%$15.22 (−36.53%)
May 5, 2026
21w ago
Press Release
BEARISH ★ 6/10
$25.93 $22.41▲ +13.57%▲ +16.36%$15.22 (+41.30%)
May 1, 2026
22w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.77 $22.85▼ −7.75%▼ −13.04%$15.22 (−38.55%)
Apr 2, 2026
26w ago
8-K
BULLISH ★ 8/10
$22.45 $24.69▲ +9.98%▲ +0.10%$15.22 (−32.20%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (64h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 6, 2026